The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Exciting updates in R/R multiple myeloma: highlights at ASH 2022
Dan Vogl, University of Pennsylvania, Philadelphia, PA, discusses exciting updates in the treatment of relapsed/refractory multiple myeloma (R/R MM) presented at ASH 2022, highlighting the promise of bispecific T-cell engagers (BiTEs), GPRC5D-directed CAR-T therapy, and novel agents, including mezigdomide. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
